Immix Biopharma (IMMX) Projected to Post Quarterly Earnings on Thursday

Immix Biopharma (NASDAQ:IMMX) is projected to release its earnings data on Thursday, March 27th. Analysts expect Immix Biopharma to post earnings of ($0.25) per share for the quarter.

Immix Biopharma Price Performance

Shares of IMMX opened at $1.95 on Thursday. Immix Biopharma has a 1-year low of $1.26 and a 1-year high of $3.35. The company has a 50-day moving average of $1.88 and a 200 day moving average of $1.87. The firm has a market capitalization of $53.64 million, a price-to-earnings ratio of -2.29 and a beta of 0.26.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price objective on shares of Immix Biopharma in a report on Monday, February 10th.

Immix Biopharma Company Profile

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.